Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Compumedics Limited ( (AU:CMP) ) has issued an update.
Compumedics Limited reported a pivotal year in FY25, achieving record sales orders and revenue while advancing its growth agenda. The company saw a 22% increase in sales orders to $63.4 million and a 2% rise in revenue to $51.0 million, driven by strong performance in sleep diagnostics and SaaS, as well as renewed traction in the U.S. market. Despite a decrease in MEG revenue, underlying growth was approximately 13% when excluding this segment. The momentum in the U.S. and Asia positions Compumedics for a strong start to FY26.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
More about Compumedics Limited
Compumedics Limited operates in the medical technology industry, focusing on sleep diagnostics, neuro-diagnostics, brain research, and ultrasonic blood flow. The company is known for its innovative solutions in these high-value markets, with a particular emphasis on expanding its global commercial reach and advancing new product platforms.
Average Trading Volume: 84,047
Technical Sentiment Signal: Buy
Current Market Cap: A$59.59M
See more insights into CMP stock on TipRanks’ Stock Analysis page.